-
Addex Therapeutics Starts Mid-Stage Study For Dipraglurant In Parkinson's Associated Dyskinesia
Tuesday, June 29, 2021 - 8:58am | 234Read More...Addex Therapeutics Ltd (NASDAQ: ADXN) has started patient screening for its Phase 2b/3 study evaluating dipraglurant for dyskinesia associated with Parkinson's disease (PD-LID). Dyskinesia is believed to be caused by increased glutamatergic neurotransmission. ...
-
Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside
Wednesday, April 12, 2017 - 12:57pm | 404Read More...Shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) soared by more than 20 percent Wednesday after the U.S. Food and Drug Administration granted approval for the company's Ingrezza therapy. Ingrezza is used by adults with tardive dyskinesia (TD) and has become the first treatment option...
